FDA found Listeria in fresh enoki mushrooms imported by La Yongjia Trade Co., which lacked a Foreign Supplier Verification Program (FSVP).
What happened
FDA conducted an FSVP inspection at La Yongjia Trade Co. in Vernon, CA, from February 15 through February 23, 2023. FDA initiated it after Listeria monocytogenes was found in samples of fresh enoki mushrooms from the company's foreign suppliers; several suppliers were on FDA import alerts that allow detention without physical examination. During the inspection, FDA found the company had no FSVP for any foods it imports, and the company did not respond to the Form FDA 483 inspection observations.
What FDA found
The company did not develop, maintain, or follow a Foreign Supplier Verification Program (FSVP) for any foods it imports, including fresh enoki mushrooms.
section 805 of the FD&C Act; 21 CFR 1.502(a)The company did not have a written hazard analysis for the foods it imports.
21 CFR 1.504The company did not evaluate its foreign suppliers' performance.
21 CFR 1.505The company did not conduct foreign supplier verification activities.
21 CFR 1.506The company gave sample analysis results for some shipments, but they were incomplete as an FSVP and lacked a record of review or explanation of how they applied.
section 805 of the FD&C Act; 21 CFR 1.502(a)As an importer of fresh produce covered by the produce safety rule, the company lacked an FSVP showing its suppliers meet at least the same public health protection as that rule.
section 419 of the FD&C Act; 21 CFR part 112
What FDA wants
FDA asks the company to respond in writing within 15 working days, describing corrections and providing documentation such as a copy of its FSVP and records showing implementation. If corrections cannot be completed in 15 days, the company must explain the delay and state when it will finish.
Who should pay attention
- fresh produce importers
- retailers and distributors selling enoki mushrooms
- food brands sourcing from foreign mushroom suppliers
This is a summary. Read the original letter on fda.gov.